Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618618 | 0.84 | ALOX15 (0.55) | CA2IGF1RALOX15CA1HSD17B10 | |
| SCHEMBL27721246 | 0.79 | MAPT (0.39) | IGF1RALOX15HSD17B10CYP3A4CYP2D6 | |
| SCHEMBL9773533 | 0.79 | CA2 (0.61) | CA2IGF1RALOX15CA1HSD17B10 | |
| SCHEMBL13892908 | 0.78 | PKM (0.45) | IGF1RALOX15TSHR | |
| SCHEMBL27650080 | 0.77 | LCK (0.63) | CA2ALOX15CA1HSD17B10CYP3A4 | |
| SCHEMBL15471711 | 0.76 | PNMT (0.39) | HSD17B10 | |
| SCHEMBL4373378 | 0.76 | TAAR1 (0.61) | CYP1A2CYP3A4CYP2C9CYP2C19HSD17B2 | |
| SCHEMBL27648819 | 0.76 | ALDH1A1 (0.47) | TSHR | |
| SCHEMBL9745836 | 0.75 | IGF1R (0.66) | CA2IGF1RALOX15CA1HSD17B10 | |
| SCHEMBL17541809 | 0.74 | TSHR (0.46) | CYP1A2CYP3A4CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2208727-B1 | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | CA2 2723/4885IGF1R 1556/4885ALOX15 2139/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | CA2 2686/4885IGF1R 1491/4885ALOX15 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.